ATE226831T1 - Impfstoff gegen mittelohrentzündung - Google Patents

Impfstoff gegen mittelohrentzündung

Info

Publication number
ATE226831T1
ATE226831T1 AT94922428T AT94922428T ATE226831T1 AT E226831 T1 ATE226831 T1 AT E226831T1 AT 94922428 T AT94922428 T AT 94922428T AT 94922428 T AT94922428 T AT 94922428T AT E226831 T1 ATE226831 T1 AT E226831T1
Authority
AT
Austria
Prior art keywords
fimbrin
vaccine against
ear inflammation
entire ear
against entire
Prior art date
Application number
AT94922428T
Other languages
English (en)
Inventor
Pappachan E Kolattukudy
Lauren O Bakaletz
Tatiana Sirakova
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of ATE226831T1 publication Critical patent/ATE226831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94922428T 1993-05-18 1994-05-12 Impfstoff gegen mittelohrentzündung ATE226831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6544293A 1993-05-18 1993-05-18
PCT/US1994/005477 WO1994026304A1 (en) 1993-05-18 1994-05-12 Otitis media vaccine

Publications (1)

Publication Number Publication Date
ATE226831T1 true ATE226831T1 (de) 2002-11-15

Family

ID=22062752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94922428T ATE226831T1 (de) 1993-05-18 1994-05-12 Impfstoff gegen mittelohrentzündung

Country Status (9)

Country Link
US (3) US5766608A (de)
EP (2) EP0699076B1 (de)
JP (1) JP3429313B2 (de)
AT (1) ATE226831T1 (de)
DE (1) DE69431624T2 (de)
DK (1) DK0699076T3 (de)
ES (1) ES2185658T3 (de)
PT (1) PT699076E (de)
WO (1) WO1994026304A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3429313B2 (ja) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン
EP1624068A1 (de) * 1993-06-01 2006-02-08 Life Technologies Inc. Genetische Impfung mit kationischen Lipidstoffen
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
EP1667712B1 (de) 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
ATE488526T1 (de) * 2005-07-08 2010-12-15 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae- induzierte infektion
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
CA2690708A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
WO2009103068A1 (en) 2008-02-15 2009-08-20 Life Technologies Corporation Methods and compositions for shearing of polymers by sonication
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CA2792687A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CA2838188C (en) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
WO2014138748A1 (en) 2013-03-08 2014-09-12 Research Institute At Nationwide Children's Hospital Transcutaneous dosage formulation
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
EP3833382A1 (de) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Verfahren und impfstoffe
EP3886901A1 (de) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Verfahren zur herstellung eines adjuvans
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (de) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Kontinuierliches verfahren zur herstellung von impfstoffen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5110908A (en) * 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
JP3429313B2 (ja) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン

Also Published As

Publication number Publication date
US6562349B1 (en) 2003-05-13
US6030626A (en) 2000-02-29
JPH09500104A (ja) 1997-01-07
DK0699076T3 (da) 2003-03-03
DE69431624D1 (de) 2002-12-05
WO1994026304A1 (en) 1994-11-24
DE69431624T2 (de) 2003-07-10
EP0699076A1 (de) 1996-03-06
US5766608A (en) 1998-06-16
PT699076E (pt) 2003-03-31
EP0699076B1 (de) 2002-10-30
ES2185658T3 (es) 2003-05-01
EP0699076A4 (de) 1999-09-08
EP1300156A2 (de) 2003-04-09
EP1300156A3 (de) 2003-05-07
JP3429313B2 (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
ATE226831T1 (de) Impfstoff gegen mittelohrentzündung
NO953033D0 (no) Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse
HUP9801638A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló proteáz K variánsok
IL114809A0 (en) Mutant br96 antibodies
ATE189477T1 (de) Mutierte penicillin-g-acylase gene
US5786464C1 (en) Overexpression of mammalian and viral proteins
ATE389666T1 (de) Hohe expressionsrate von proteinen
DK0851868T3 (da) Höjniveau-ekspression af proteiner
FI943389L (fi) Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö
DE69129604D1 (de) Mutierte beta-Lactamacylasegene
DE3770915D1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
ATE255165T1 (de) Rekombinantes mersacidin und verfahren zu seiner herstellung
HUP9800767A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló szubtilizin DY variánsok
GR3019059T3 (en) Human MK gene and protein sequence
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
HUP9802069A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló termitáz variánsok
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
AU9730798A (en) Epoxide hydrolase
WO2001044289A3 (en) Modified leukotoxin gene and protein
AU4496196A (en) Recombinant DNA comprising DNA coding for myosin heavy chain SM1 isoform protein inserted into vector DNA, microorganism carrying the recombinant DNA, and an agent for treatment of arteriosclerosis comprising the recombinant DNA
FI960951A0 (fi) Akarboosibiosynteesigeenejä Actinoplanes sp:stä, menetelmiä niiden eristämiseksi sekä niiden käyttö
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
AU2002359572A1 (en) 15603, a human ion channel family member

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0699076

Country of ref document: EP

REN Ceased due to non-payment of the annual fee